股浅动脉原发支架置入改善间歇性跛行患者生活质量、ABI与步行距离:随机对照试验12个月结果
12个月随访显示,支架组在健康相关生活质量、踝肱指数和步行距离方面均显著优于对照组。
要点
- 股浅动脉原发支架置入联合最佳药物治疗可显著改善间歇性跛行患者12个月生活质量。
- 支架组踝肱指数和步行距离在12个月时均显著高于单纯药物治疗组。
- 单纯最佳药物治疗组生活质量评分未见显著变化。
核心结论
- 在股浅动脉病变所致间歇性跛行患者中,原发支架置入联合最佳药物治疗与单纯最佳药物治疗相比,12个月随访时健康相关生活质量、踝肱指数和步行距离均显著改善。
研究设计与样本
- 主要结局为12个月时SF-36和EQ5D评估的健康相关生活质量变化,次要结局包括WIQ、ABI和步行距离改善。
主要发现
- 支架组SF-36多个领域显著改善:躯体功能提高19分(p < .001),躯体疼痛提高14分(p = .001),总体健康提高6分(p = .019),活力提高10分(p = .004),躯体成分总结提高6.5分(p < .001)。
- 支架组EQ5D提高0.14分(p = .008),WIQ提高22分(p < .001),对照组上述指标无变化。
- 支架组ABI从0.58 ± 0.11升至0.86 ± 0.19(p < .001),对照组从0.63 ± 0.17升至0.70 ± 0.20(p = .005)。
- 支架组步行距离从171 ± 90米增至613 ± 381米(p < .001),对照组从209 ± 106米增至335 ± 321米(p = .012)。
- 12个月时支架组ABI(p < .001)和步行距离(p = .001)均高于对照组。
临床怎么用
- 对于股浅动脉严重狭窄或闭塞所致稳定间歇性跛行患者,可考虑在最佳药物治疗基础上行原发镍钛自膨式支架置入以改善生活质量和步行能力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Invasive treatment of intermittent claudication (IC) because of severe atherosclerotic stenosis or occlusion in the superficial femoral artery (SFA) is controversial. This prospective randomised trial was performed to assess the impact on health related quality of life (HRQoL) of primary stenting with nitinol self expanding stents compared with best medical treatment alone in patients suffering from stable IC due to SFA disease. METHODS: One hundred patients with stable IC caused by SFA disease from seven Swedish hospitals treated with best medical treatment (BMT) were randomised to either the stent (n = 48) or the control (n = 52) group. Change in HRQoL assessed by the Short Form 36 Health Survey (SF-36) and EuroQoL 5 dimensions (EQ5D) 12 months after treatment was the primary outcome measure. Improvement in the Walking Impairment Questionnaire (WIQ), ankle brachial index (ABI), and walking distance were secondary outcomes. RESULTS: HRQoL improved significantly. In the stent group the following SF-36 domains improved: Physical Function, 19 points (p < .001); Bodily Pain, 14 points (p = .001); General Health, 6 points (p = .019); Vitality, 10 points (p = .004); Physical Component Summary, 6.5 points (p < .001); EQ5D, 0.14 points (p = .008); and WIQ 22 points (p < .001). They were unchanged in the control group. Both ABI (from 0.58 ± 0.11 to 0.86 ± 0.19, p < .001, in the stent group and from 0.63 ± 0.17 to 0.70 ± 0.20, p = .005, in the control group) and walking distance (WD) (from 171 ± 90 meters to 613 ± 381 meters, p < .001, in the stent group and from 209 ± 106 m to 335 ± 321 meters, p = .012, in the control group) improved, and at 12 months both the ABI (p < .001) and the WD (p = .001) were higher in the stent group. CONCLUSIONS: In patients with IC caused by lesions in the SFA, the addition of primary stenting to BMT was associated with significant improvement in HRQoL, ABI, and walking distance after 12 months follow-up compared with BMT alone.
引用
- Lindgren H, Qvarfordt P, Åkesson M, et al. Primary Stenting of the Superficial Femoral Artery in Intermittent Claudication Improves Health Related Quality of Life, ABI and Walking Distance: 12 Month Results of a Controlled Randomised Multicentre Trial. Eur J Vasc Endovasc Surg. 2017. PMID: 28372983. doi:10.1016/j.ejvs.2017.01.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。